BRPI0911678B8 - maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central - Google Patents

maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central

Info

Publication number
BRPI0911678B8
BRPI0911678B8 BRPI0911678A BRPI0911678A BRPI0911678B8 BR PI0911678 B8 BRPI0911678 B8 BR PI0911678B8 BR PI0911678 A BRPI0911678 A BR PI0911678A BR PI0911678 A BRPI0911678 A BR PI0911678A BR PI0911678 B8 BRPI0911678 B8 BR PI0911678B8
Authority
BR
Brazil
Prior art keywords
maleate
prophylaxis
treatment
pharmaceutical composition
nervous system
Prior art date
Application number
BRPI0911678A
Other languages
English (en)
Inventor
Sartor Franco
Philip Steeples Ian
Beato Stefania
Original Assignee
Glaxo Group Ltd
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Nerre Therapeutics Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0911678A2 publication Critical patent/BRPI0911678A2/pt
Publication of BRPI0911678B1 publication Critical patent/BRPI0911678B1/pt
Publication of BRPI0911678B8 publication Critical patent/BRPI0911678B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

forma cristalina anidrosa de maleato de orvepitant a invenção refere-se ao maleato de orvepitant cristalino anidroso (forma 1), composições farmacêuticas compreendendo o mesmo, seu uso em terapia e processos para preparar o mesmo.
BRPI0911678A 2008-04-11 2009-04-09 maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central BRPI0911678B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0806652.4 2008-04-11
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate
PCT/EP2009/054295 WO2009124996A1 (en) 2008-04-11 2009-04-09 Anhydrous crystal form of orvepitant maleate

Publications (3)

Publication Number Publication Date
BRPI0911678A2 BRPI0911678A2 (pt) 2015-10-13
BRPI0911678B1 BRPI0911678B1 (pt) 2021-03-02
BRPI0911678B8 true BRPI0911678B8 (pt) 2021-05-25

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911678A BRPI0911678B8 (pt) 2008-04-11 2009-04-09 maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central

Country Status (27)

Country Link
US (1) US8309553B2 (pt)
EP (1) EP2297152B1 (pt)
JP (2) JP5875863B2 (pt)
KR (1) KR20110002090A (pt)
CN (1) CN102066376B (pt)
AR (1) AR071311A1 (pt)
AU (1) AU2009235440B2 (pt)
BR (1) BRPI0911678B8 (pt)
CA (1) CA2721119C (pt)
CL (1) CL2009000876A1 (pt)
CY (1) CY1115961T1 (pt)
DK (1) DK2297152T3 (pt)
EA (1) EA017082B1 (pt)
ES (1) ES2529295T3 (pt)
GB (1) GB0806652D0 (pt)
HR (1) HRP20141196T1 (pt)
IL (1) IL208597A0 (pt)
MX (1) MX2010011152A (pt)
PE (1) PE20091839A1 (pt)
PL (1) PL2297152T3 (pt)
PT (1) PT2297152E (pt)
RS (1) RS53732B1 (pt)
SI (1) SI2297152T1 (pt)
TW (1) TW201002714A (pt)
UY (1) UY31758A (pt)
WO (1) WO2009124996A1 (pt)
ZA (1) ZA201007120B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056151A1 (en) * 2007-10-30 2009-05-07 Elekta Ab (Publ) Radiotherapy apparatus
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
WO2014057003A1 (en) * 2012-10-11 2014-04-17 Nerre Therapeutics Limited Novel uses
ES2738678T3 (es) * 2016-01-08 2020-01-24 Nerre Therapeutics Ltd Orvepitant para el tratamiento de la tos crónica
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
BR112022018876A2 (pt) * 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2009538334A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2011503449A (ja) * 2007-11-02 2011-01-27 インテグリス・インコーポレーテッド Ｏリングが不要なシール連結部
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
TW201002714A (en) 2010-01-16
HRP20141196T1 (hr) 2015-02-13
JP2011516532A (ja) 2011-05-26
IL208597A0 (en) 2010-12-30
CN102066376B (zh) 2014-01-01
SI2297152T1 (sl) 2015-02-27
CY1115961T1 (el) 2017-01-25
MX2010011152A (es) 2010-12-21
CA2721119C (en) 2016-04-05
WO2009124996A1 (en) 2009-10-15
EA017082B1 (ru) 2012-09-28
PE20091839A1 (es) 2010-01-07
EP2297152B1 (en) 2014-11-12
AR071311A1 (es) 2010-06-09
EP2297152A1 (en) 2011-03-23
EA201071183A1 (ru) 2011-06-30
BRPI0911678A2 (pt) 2015-10-13
CL2009000876A1 (es) 2010-05-14
PL2297152T3 (pl) 2015-04-30
GB0806652D0 (en) 2008-05-14
US8309553B2 (en) 2012-11-13
UY31758A (es) 2009-11-10
CA2721119A1 (en) 2009-10-15
AU2009235440A1 (en) 2009-10-15
JP5875863B2 (ja) 2016-03-02
RS53732B1 (sr) 2015-06-30
US20110166150A1 (en) 2011-07-07
KR20110002090A (ko) 2011-01-06
AU2009235440B2 (en) 2012-06-14
ES2529295T3 (es) 2015-02-18
DK2297152T3 (da) 2015-01-26
JP2014205688A (ja) 2014-10-30
ZA201007120B (en) 2011-11-30
CN102066376A (zh) 2011-05-18
PT2297152E (pt) 2015-02-16
BRPI0911678B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
MX2011009847A (es) Agentes antihelminticos y su uso.
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
CL2008003473A1 (es) Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro.
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
CO6690805A2 (es) 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3
AU2009282962A8 (en) Compounds as kinase inhibitors
ATE520668T1 (de) Sigmarezeptor-inhibitoren
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
MY150931A (en) Substituted oxazolidinones and their use
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
CL2009000876A1 (es) Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
MX2013006004A (es) Derivados de 5-metil-1-(naftalen-2-il)-1h-pirazol y su uso en potencializar el efecto de los analgesicos opioides.
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: GLAXO GROUP LIMITED (GB)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130082868 DE 15/10/2013, E NECESSARIO APRESENTAR O DOCUMENTO COM A DEVIDA LEGALIZACAO CONSULAR.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GLAXO GROUP LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: NERRE THERAPEUTICS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF